Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 16, 2019Appointment reinforces Armata's commitment to develop Pseudomonas phage product candidates
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
-
Oct 10, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
-
Sep 19, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
Sep 12, 2019Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
-
Aug 14, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
-
Aug 1, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
Jun 18, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
Jun 3, 2019Patent allowances cover various aspects of the Company's phage program and lead product candidate, AP-SA01
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
May 28, 2019Armata's bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
May 9, 2019Shares of the combined company to commence trading on the NYSE American exchange under the new symbol "ARMP" on May 10, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...